News & Publications
  • Congratulations to Pro. Lu Chao’s team for their article published on Nature
    Congratulations to Pro. Lu Chao’s team for their article published on Nature Sep 05, 2019
    Recently, Lu Chao’s team have published their paper on Nature entitled "The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape". Enzymes that catalyse CpG methylation in DNA, including the DNA methyltransferases 1 (DNMT1), 3A (DNMT3A) and 3B (DNMT3B), are indispensable for mammalian tissue development and homeostasis. They are also implicated in human developmental disorders and cancers, supporting the critical role of DNA methylation in the specification and maintenance of cell fate. Previous studies have suggested that post-translational modifications of histones are involved in specifying patterns of DNA methyltransferase localization and DNA methylation at promoters and actively transcribed gene bodies. However, the mechanisms that control the establishment and maintenance of intergenic DNA methylation remain poorly understood. Tatton–Brown–Rahman syndrome (TBRS) is a childhood overgrowth disorder that is defined by germline mutations in DNMT3A. TBRS shares clinical features with Sotos syndrome (which is caused by haploinsufficiency of NSD1, a histone methyltransferase that catalyses the dimethylation of histone H3 at K36 (H3K36me2), which suggests that there is a mechanistic link between these two diseases. Here we report that NSD1-mediated H3K36me2 is required for the recruitment of DNMT3A and maintenance of DNA methylation at intergenic regions. Genome-wide analysis shows that the binding and activity of DNMT3A colocalize with H3K36me2 at non-coding regions of euchromatin. Genetic ablation of Nsd1 and its paralogue Nsd2 in mouse cells results in a redistribution of DNMT3A to H3K36me3-modified gene bodies and a reduction in the methylation of intergenic DNA. Blood samples from patients with Sotos syndrome and NSD1-mutant tumours also exhibit hypomethylation of intergenic DNA. The PWWP domain of DNMT3A shows dual recognition of H3K36me2 and H3K36me3 in vitro, with a higher binding affinity towards H3K36me2 that is abrogated by TBRS-derived missense mutations. Together, our study reveals a trans-chromatin regulatory pathway that connects aberrant intergenic CpG methylation to human neoplastic and developmental overgrowth. We are honored to provide the H3 post-translational modified histones for the research. We can also provide you with customized synthetic services for functional proteins and polypeptides,like H3,H3-K4me1,H2A-K119Ub,CENPA-S17ph. KS-V Peptide specializes in providing customized synthesis of difficult peptides , modification and optimization of pharmaceutical peptide and development of peptide technology for universities, research institutes and biopharmaceutical companies. Link for the article:https://doi.org/10.1038/s41586-019-1534-3
    Read More
  • KS-V Peptide won the second prize in the Final of Hefei District Competition of the 8th China Innovation and Entrepreneurship Competition
    KS-V Peptide won the second prize in the Final of Hefei District Competition of the 8th China Innovation and Entrepreneurship Competition Jul 31, 2019
    On July 30th, it successfully held the “Technology Bank Cup”of the 8th China Innovation and Entrepreneurship Competition of Hefei District in Hefei. All the companies selected for the final are outstanding. Most researchs of the enterprises’ core teams are highly educated talents,doctors of Science and Technology University of China, Harvard University's post-doctoral research talents, and the world's original technology,for instance. With the top peptide synthesis technology and broad market prospects, KS-V Peptide has won the second prize of Biomedicine Group. KS-V Peptide have a first-class scientific research and has rich experience in production, management, marketing team,we will create a new chapter of innovation and entrepreneurship in Hefei,namely to contribute  to create innovative cities with a mode of science and technology.
    Read More
  • KS-V Peptide Participated in the 19th CPhI China<br>——Embedding into the Global Pharmaceutical Value Chain
    KS-V Peptide Participated in the 19th CPhI China
    ——Embedding into the Global Pharmaceutical Value Chain
    Jun 27, 2019
    A three-day itinerary of KS-V Peptide to the 19th CPhI China came to a successful conclusion. As a global event of the international pharmaceutical industry, CPhI is a comprehensive platform for displaying images, promoting brands and releasing new products, attracting a large number of outstanding enterprises and professional representatives from around the world. KS-V Peptide has become a highlight in the exhibition with its strong scientific and technological innovation strength and high-quality products. Many potential customers visited our booth to consult the products during the exhibition. At present, biopharmaceuticals have become the fastest growing, most energetic and most technologically advanced areas in the pharmaceutical industry. Domestic and foreign pharmaceutical companies are rushing to development. Hefei KS-V Peptide Biological Technology Co., Ltd.(KSVP) specializes in providing customized synthesis of difficult peptides (including Toxins and Analogues, Ubiquitins and Ubiquitin Probes, Post-transcriptional Histones and Nucleosome Assembly), modification and optimization of pharmaceutical peptide(PEG, Alkylation Modification, etc.)and development of peptide technology for universities, research institutes and biopharmaceutical companies. In the field of peptides chemical synthesis, KS-V Peptide owns many unique or international leading technical abilities for the synthesis of difficult peptides. KS-V Peptide shows its specialization, internationalization and high-end through this Expo. By keeping faith with the service concept of safety first, quality first, high efficiency and innovation, adhering to the customer-centered service purpose and carrying out quality control in accordance with the requirements of ISO9001:2015, KSVP is committed to providing diversified and point-to-point precise products and services to meet the diverse needs of different customers.
    Read More
First 1 2 Last
[  A total of  2  pages]
Request a Quote
Please send us your inquiry(including peptide sequences,purity,quantity,modifications notes, etc.)by message. We will contact  you as soon as possible, usually in 24h in working days. Please send the email to: sales@difficultpeptide.com for bulk order of peptides. Thank you!
Leave a message

Leave a message

    If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

news

Contact